KRMD Stock Forecast & Price Target

KORU Medical Systems Inc. demonstrated strong financial performance in its recent quarterly results, reporting revenues of $9.6 million which represented a 17.5% year-over-year increase, driven by significant growth in both U.S. and international markets at 16% and 36%, respectively. The company also exhibited improved gross margin percentage, which expanded by 50 basis points year-over-year to reach 62.8%, highlighting effective cost management amidst geographic shifts in its sales mix. Additionally, management’s decision to raise 2025 revenue guidance by $0.5 million, along with plans to submit for approval of two commercialized drugs, underscores a positive trajectory for the business and its product offerings in the medical device sector.

KORU Medical Systems reported an operating loss of $1.2 million, indicating underlying financial challenges despite the positive performance metrics related to its FREEDOM Infusion Systems. The company demonstrates a negative trend in profitability, as evidenced by the substantial operating loss, which raises concerns about its operational efficiency and cost management. Additionally, the financial performance metrics suggest that the company is not keeping pace with market expectations, further contributing to a pessimistic outlook on its future viability.